Prothena Corp. (PRTA) Prices 3.5M Offering of Ordinary Shares at $20.75/sh

Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that it priced an underwritten public offering of 3,500,000 of its ordinary shares at a price to the public of $20.75 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 525,000 of its ordinary shares.

Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $67.8 million, after deducting the underwriting discount and estimated offering expenses, but excluding any exercise of the underwriters’ option to purchase additional ordinary shares. The offering is expected to close on March 26, 2021, subject to customary closing conditions.

Citigroup, Jefferies and Cantor are acting as lead book-running managers, Oppenheimer & Co. is acting as book-running manager, and BTIG and H.C. Wainwright & Co. are acting as co-lead managers for the offering.

You May Also Be Interested In

• Mr. Cooper Group (COOP) Appoints Ranjit Bhattacharjee as CIO and President, Kevin Barker as SVP of Corporate Finance
• Jefferies Upgrades Medpace (MEDP) to Buy, 'Big Margin Improvements'
• Jefferies Upgrades Ingevity Corp (NGVT) to Buy, 'Activated Carbon Solid, Intermediate Chemicals Rebound Likely'